Trials / Terminated
TerminatedNCT02228785
A Study of the Safety and Tolerance of Three Doses of G17DT in Metastatic Colorectal Cancer
Study of the Safety and Tolerance of Three Doses of G17DT in Patients With Metastatic Colorectal Cancer.
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- Cancer Advances Inc. · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study was designed to investigate the safety and tolerance of three doses (100µg, 200µg, 500µg) of G17DT for the treatment of patients with colorectal cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | G17DT |
Timeline
- Start date
- 1994-05-01
- Primary completion
- 1994-10-01
- First posted
- 2014-08-29
- Last updated
- 2014-08-29
Source: ClinicalTrials.gov record NCT02228785. Inclusion in this directory is not an endorsement.